ANGPTL3 and atherosclerosis: Whether the substantial reductions in LDL-C and other atherogenic lipid and lipoprotein profiles with evinacumab and other ANGPTL3 inhibitors translates into a decrease in ASCVD events or improvement in vascular function and/or arterial inflammation in HoFH remains to be shown.